Epidemiological Profile, Gastrointestinal Toxicity, and Treatment of Pelvic Cancers in Patients Managed with Radiotherapy to the Abdominal Pelvic Area

• Lucely del Rosario Cetina Pérez ; Alberto Serrano Olvera ; Laura Flores Cisneros ^[2] ; Roberto Jiménez Lima ^[2] ; Cristina Alvarado Silva ^[1] ; María del Consuelo Díaz Romero ^[2] ; Flavia Morales Vásquez ; David Eduardo Muñoz González ^[2] ; Aida Mota García ; Oscar Armando Chávez Fierro ^[2] ; Silvia Cristina Jaramillo Manzur ^[2] ; Jaime de la Garza- Salazar ^[2] ; Denisse Castro Eguiluz ; Abelardo Meneses García
  1. [1] Hospital Juárez de México

     Hospital Juárez de México

     México

     
  2. [2] Instituto Nacional de Cancerología (MEX)
• Localización: Revista de investigación clínica, ISSN 0034-8376, ISSN-e 2564-8896, Vol. 70, Nº. 3, 2018, págs. 112-116
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Mexico has seen an increase in cancer prevalence in its entire population as well as particular age ranges, predominantly the older segment. The most frequently reported pelvic cancers in Mexico are cervical, endometrial, bladder, prostate, rectum, and anal canal. Approximately 80% of the population diagnosed with pelvic cancers present with locally advanced tumors and require concomitant chemoradiotherapy, sequential chemoradiotherapy, or radiotherapy alone. The toxicity of any of these treatment modalities may be manifested as intestinal injury, a significant problem that can compromise the response to treatment, the patient’s nutritional state, quality of life, and survival. In this article, we will approach key aspects in nutrition as well as the epidemiological characteristics and toxicities in patients affected by these pelvic tumors. (REV INVES CLIN. 2018;70:112-6)